Hormone refractory metastatic prostate cancer. Ann Oncol 1992;3(5):331 A/5.Sternberg CN: Hormone refractory metastatic prostate cancer. Ann Oncol 3:331-335, 1992Sternberg, C.N. (1992) Hormone refractory metastatic prostate cancer. Ann. Oncol. 3, 331-335....
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol, 10 (1992), pp. 881-889 Google Scholar 45. van Oosterom AT, De Smedt EA, Denis LJ, de Bruijn EA, Mahler C Suramin for prostatic cancer: a phase I/II study in advanced ...
Objective: Patients with metastatic hormone-refractory prostate cancer have a poor overall survival rate. Newer agents have shown promise in slowing disease progression but are mostly ineffective in improving the overall survival rate, are toxic, and require intravenous administration. In an attempt to ...
这是被批准用于治疗激素抵抗性前列腺癌(hormone refractory prostate cancer)的首个药物。该药已显示出有促进患者生存的 … www.oneyao.net|基于10个网页 2. 激素非依赖性前列腺癌 ... )hormone refractory prostate cancer激素非依赖性前列腺癌) androgen-dependence prostate cancer 雄激素依赖性前列腺癌 ... ...
To evaluate the safety and toxicity of peptide vaccination for patients with metastatic hormone-refractory prostate cancer (HRPC) based on pre-existing peptide-specific cytotoxic T-lymphocyte (CTL) precursors in the circulation, 10 patients positive for human leukocyte antigen (HLA)-A2 with metastatic...
( 2004 ) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer . N Engl J Med 351 : 1513 – 1520 Synopsis Background Mitoxantrone (Novantrone ; OSI, Melville, NY) plus corticosteroids for metastatic androgen-independent prostate cancer relieves ...
In 2004, the TAX 327 study investigators reported that high-dose docetaxel given every 2 weeks produced better survival outcomes than mitoxantrone in men with metastatic hormone-refractory prostate cancer (HRPC). In their updated analysis of this trial, Berthold et al. confirm the survival benefit ...
Hormone-refractory prostate cancer (HRCaP) is both heterogeneous and lethal. Multiple treatment options exist, including secondary hormonal manipulations, chemotherapy, experimental options, and best supportive care. Choosing the appropriate therapy for an individual patient depends on several ...
Hormone-refractory prostate cancer (HRPC) encompasses a wide spectrum of patients, including patients with prostate-specific antigen (PSA)–only disease, those with increasing PSA levels yet stable metastatic disease, and those with increasing PSA levels and objective evidence of progressive metastases. ...
castrate resistant prostate cancermicrotubule inhibitorEribulin mesylate, a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits cancer cell proliferation at low-nanomolar levels. In a multicenter ECOG trial, patients with progressive metastatic CRPC, ECOG 0-2 were ...